Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 1023-1037

  Hamilton Craig, Ian ^a   Kostner, Karam ^b   Colquhoun, David ^b   Woodhouse, Stan ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Combination therapy; Ezetimibe; Familial hypercholesterolemia; Low density lipoprotein cholesterol; Statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MONOTHERAPY; MUSCLE CRAMP; MUSCLE STIFFNESS; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79956268616     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S13496     Document Type: Review

References (107)

1. Product information for ezetimibe. http://www.msppharma.com/msppharma/documents/zetia_pi.pdf. Accessed 2010 May 1.
2. National Cholesterol Education Program (NCEP). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation. 2002; 106:3143-3421.
3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
4. Hegele RA, Guy J, Ban MR, Wang J. NPC1 L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis. 2005;4:16.
5. Tonkin A, Barter P, Best J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management - 2005. Heart Lung Circ. 2005;14:275-291.
6. Lakoski S, Xu F, Vega GL, et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab. 2010;95:800-809.
7. Charles Z, Pugh E, Barnett D. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolemia: NICE technology appraisal guidance. Heart. 2008;94(5):642-643.
8. Sharma M, Ansari MT, Soares-Weiser K, et al. Comparative Effectiveness of Lipid-modifying Agents. Health Services/ Technology Assessment Text. AHRQ Comparative Effectiveness Reviews. Available at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hscompeff&part=cer16. Accessed 2010 Jun 14.
9. Knopp RH, Gitter H, Truitt T, et al. Ezetimibe reduces low-density lipoprotein cholesterol: results of a phase III, randomized, double-blind, placebo-controlled trial. Atherosclerosis. 2001;2(2):38.
10. Lipka L, Kerzner B, Crobelli J, et al. Results of ezetimibe co-administered with lovastatin in 548 patients with primary hypercho-lesterolemia. J Am Coll Cardiol.2002;39(9 Suppl B):430B.
11. Simons L, Musliner T, Quinto K, Cho M, Gumbiner B. Ezetimibe added to on-going statin therapy for treatment of primary hyper-cholesterolemia: Efficacy and safety in patients with type 2 diabetes mellitus. Diabetologia. 2002;45 Suppl 2:A389.
12. Ballantyne C, Houri J, Notarbatolo A, et al; Ezetimibe Study Group. Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002; 39 Suppl A:227A.
13. Bays H, Weiss S, Gagne C, et al. Ezetimibe added to ongoing statin therapy for treatment of primary hypercholesterolemia. J Am Coll Cardiol. 2002;39 Suppl A:245A.
14. Davidson M, McGarry T, Bettis R, et al. Ezetimibe Study Group. Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholesterolemia. J Am Coll Cardiol.2002;39 Suppl A:226A-227A.
15. Dujovne C, Held J, Lipka L, LeBeaut A, Suresh R, Veltri E; Ezetimibe Study Group. Does Cholesterol and/or fat intake affect plasma lipid Efficacy of ezetimibe? J Am Coll Cardiol. 2002; 39 Suppl A: 227A.
16. Dujovne CA, Ettinger MP, McNeer JF, et al. Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1092-1097.
17. Gagne C, Bays HE, Weiss SR, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002; 90(10):1084-1091.
18. Stein E, Stender S, Mata P, et al. Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholester-olemia: Efficacy and safety of ezetimibe co-administered with atorvas-tatin. Am Heart J. 2004;148(3):447-455.
19. Xydakis AM, Guyton JR, Chiou P, Stein JL Jones PH, Ballantyne CM. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol. 2004;94(6):795-797.
20. Vermaak W, Pinto X, Ponsonnet D, et al. Heterozygous familial hypercholesterolemia: co administration of ezetimibe plus atorvastatin. Atherosclerosis. 2002;3(2):230-231.
21. Vermaak W, Pinto X, Ponsonnet D, et al. Ezetimibe Study Group. Heterozygous familial hypercholesterolemia: co administration of ezetimibe plus atorvastatin. J Am Coll Cardiol. 2003;41(6 Suppl A): 255A-255A.
22. Wierzbicki AS, Doherty E, Lumb PJ, Chik G, Crook MA. Efficacy of ezetimibe in patients with resistant familial hypercholesterolemia. Atherosclerosis. 2004;175(2):S4.
23. Wierzbicki AS, Doherty E, Lumb PJ, Chik G, Crook MA. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidemias. Curr Med Res Opin. 2005;21(3):333.
24. Metalinos G, Pitsavos C, Skoumas J, et al. The efficacy of the co-administration of ezetimibe with high dose statin therapy in heterozygous familial hypercholesterolemia patients. Atherosclerosis. 2007;8(1):207.
25. Pitsavos C, Skoumas I, Tousoulis D, et al. The impact of ezetimibe and high-dose of statin treatment of LDL levels in patients with heterozygous familial hypercholesterolemia. Int J Cardiol. 2009; 134(2):280-281.
26. Pisciotta L, Masturzo P, Bellocchio A, et al. Efficacy and safety of ezetimibe added to current therapy with statins in molecularly characterized FH patients. Atherosclerosis. 2006;7 Suppl 3:554.
27. Arteaga LIA, Cuevas MA, Rigotti RA, et al. Hypercholesterolemia familiar heterocigota: diagnostico molecular y terapia combinada. Caso clinico. [Molecular diagnosis and combined lipid lowering therapy of heterozygous familial hypercholesterolemia. Report of one case.] Rev Med Chil. 2007;135(2):2156-2120.
28. Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Atherosclerosis Thromb Vasc Biol. 2005;25(12):2654-2660.
29. Lind S, Olsson AG, Rudling M, Eriksson M, Eggertsen G, Angelin B. Signifcant reduction of plasma LDL-C in an ARH patient by adding ezetimibe. Atherosclerosis. 2004;5 Suppl 1:S85.
30. Lind S, Olsson AG, Eriksson M, Rudling M, Eggertsen G, Angelin B. Autosomal recessive hypercholesterolemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. J Intern Med. 2004;256(5):406-412.
31. Hamilton-Craig I. Familial hypercholesterolemia: walking time bombs and digging for gold. Med Today. 2008;9:39-46.
32. Bates TR, Burnett JR, van Bockxmeer FM, Hamilton S, Arnolda L, Watts GF. Detection of familial hypercholesterolaemia: a major treatment gap in preventative cardiology. Heart Lung Circ. 2008;17: 411-413.
33. Williams RR, Schumacher MC, Barlow GK, et al. Documented need for more effective diagnosis and treatment of familial hypercholester-olemia according to data from 502 heterozygotes in Utah. Am J Cardiol. 1993;72(10):18D-24D.
34. Wonderling D, Umans-Eckenhausen MA, Marks D, Defesche JC, Kastelein JJ, Thorogood M. Cost- effectiveness analysis of the genetic screening program for familial hyperc-holesterolemia in The Netherlands. Semin Vasc Med. 2004;4(1): 97-104.
35. Thorsson B, Sigurdsson G, Gudnason V. Systematic family screening for familial hypercholesterolemia in Iceland. Arterioscler Thromb Vasc Biol. 2003;23(2):335-338.
36. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis. 2005;180(1):155-160.
37. Starr B, Hadfeld SG, Hutten BA, et al. Development of sensitive and specifc age- and gender-specifc low-density lipoprotein cholesterol cutoffs for diagnosis of frst-degree relatives with familial hyper-cholesterolemia in cascade testing. Clin Chem Lab Med. 2008;46(6): 791-803.
38. Hamilton-Craig I. Case-fnding for familial hypercholesterolemia in the Asia-Pacifc region. Seminars in Vascular Med. 2004;4:87-92.
39. Umans-Eckenhausen M, Defesche J, Sijbrands E, Screeder R, Kastelein J. Review of frst 5 years of screening for familial hypercho-lesterolemia in the Netherlands. Lancet. 2001;357:165-168.
40. Kastelein JJP, Akdim F, Stroes ESG, et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443.
41. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002; 359:1379-1387.
42. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
43. Oudkerk M, Stillman AE, Halliburton SS, et al. European Society of Cardiac Radiology; North American Society for Cardiovascular Imaging. Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. Eur Radiol. 2008;18(12):2785-2807.
44. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipi-demic patients - the PRIMO study. Cardiovasc Drugs Ther. 2005;19: 403-414.
45. Bruckert E, Gagne C, Gaudet D, et al. Homozygous familial hyper-cholesterolemia: a novel therapy with ezetimibe. Atherosclerosis. 2002;3(2):81.
46. Gagne C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe co administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105(21):2469-2475.
47. Gagne C, Gaudet D, Bruckert E, et al. Ezetimibe signifcantly reduces low-density lipoprotein cholesterol in homozygous familial hyper-cholesterolemia. J Am Coll Cardiol. 2002;29(9 Suppl B):135B.
48. Gagne C, Gaudet D, Bruckert E, Ponnsonnet D, Lipka L, leBeaut A, et al; for the Exetimibe Study Group. Ezetimibe signifcantly reduces the low-density lipoprotein cholesterol in homozygous familial hyper-cholesterolemia. J Am Coll Cardiol. 2002;39 Suppl A:227A.
49. Schmidt HHJ, Tietge UJF, Buettner J, et al. Liver transplantation in a subject with familial hypercholesterolemia carrying the homozygous pW577R LDL-receptor gene mutation. Clin Transplant. 2008;22(2): 180-184.
50. Yamamato A, Harada-Shiba M, Endo M, et al. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis. 2006;86(1):126-131.
51. Kassner U, Thomas H, Steinhagen-Thiessen E, Vogt A. Intensifed lipid lowering treatment with lipid-apheresis and atorvastatin coadministered with ezetimibe in two children with homozygous familial hypercholes-terolemia. Atherosclerosis. 2004;5 Suppl 1:120.
52. Kolovou GD, Dedoussis GV, Anagnostopoulou KK, et al. Management of a patient with a null low-density lipoprotein receptor mutation: a case report. Angiology. 2006;57(6):729-732.
53. Ullah M, Ahmad SA. Familial hypercholesterolemia in a paediatric patient. J Coll Physicians Surg Pak. 2005;15(9):578-579.
54. van der Graf A, Cuffe-Jackson C, Vissers MN, et al. Efficacy and safety of co administration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008;52(17):1421-1429.
55. Clauss S, Wai KM, Kavey REW, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr. 2009;154(6): 869-872.
56. Yeste D, Chacon P, Clemente M, Albisu MA, Gussingye M, Carrascosa A. Ezetimbe as monotherapy in the treatment of hyper-cholesterolemia in children and adolescents. J Pediatr Endocrinol Metab. 2009;22(6):487-492.
57. Geiss HC, Otto C, Hund-Wissner E, Parhofer KG. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. Atherosclerosis. 2005 May;180(1):107-112.
58. Cheseaux JJ, Jotterand V, Aebi C, et al. Hyperlipidaemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Syndr. 2002;30:288-293.
59. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al; NIAD AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers;ACTG Study A5047. AIDS. 2002;16:569-577.
60. Busti AJ, Bain AM, Hall RG, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. Cardiovasc Pharmacol. 2008;51:605-610.
61. Bondi G. Addition of ezetimide to ongoing therapy with rosuvastatin in HIV patients not reaching cholesterol targets. US National Institutes of health; University of British Columbia, Vancouver BC, Canada.
62. Graf K, Dietrich T, Tachezy M, et al. Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fuorescence imaging in experimental atherosclerosis. Mol Imaging. 2008;7(2): 68-76.
63. Dietrich T, Hucko T, Bourayou R, et al. High resolution magnetic resonance imaging in atherosclerotic mice treated with ezetimibe. Int J Cardiovasc Imaging. 2009;25(8):827-836.
64. Gomez-Garre D, Munoz-Pacheco P, Gonzalez-Rubio ML, Aragoncillo P, Granados R, Fernandez-Cruz A. Ezetimibe reduces plaque infammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol. 2009;156(8):1218-1227.
65. Kuhlencordt PJ, Padmapriya P, Rützel S, et al. Ezetimibe potently reduces vascular infammation and arteriosclerosis in eNOS-defcient ApoE ko mice. Atherosclerosis. 2009;202(1):48-57.
66. Mohler ER III, Shi Y, Moore J, et al. Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol. Cytometry A. 2009;75(1):75-82.
67. Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol. 2010;633(1-3):62-70.
68. Badarin FJ, Kullo IJ, Kopecky SL, Thomas RJ. Impact of ezetimibe on atherosclerosis: is the jury still out? Mayo Clin Proc. 2009;84(4): 353-361. Comment in: Mayo Clin Proc. 2009;84(4):307-309.
69. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111:2356-2363.
70. Schmidt-Lucke C, Bojunga S, Rossig L, Heeschen C, Dimmeler S, Zeiher AM. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J. 2006;27:1182-1190.
71. Liu P-Y, Liu Y-W, Lin L-J, Chen J-H, Liao JK. Differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and infammation. Circulation. 2009;119:131-138.
72. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007;49(20):2003-2009.
73. Bass A, Hinderliter AL, Lee CR. The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. Ann Pharmacother. 2009;43:2021-2030.
74. Verhamme P, Kerkhof F, Buysschaert I, Rietzschel E, de Groot E. Carotid intima-media thickness: more than a research tool? Acta Car-diol. 2010;65(1):59-66.
75. Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA. 2008;299(14):1678-1689.
76. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52(25):2198-2205.
77. Brown BG, Taylor AJ. Does ENHANCE diminish confdence in lowering LDL or in ezetimibe? N Engl J Med. 2008;358(14):1504-1507.
78. Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol lowering and ezetimibe. N Engl J Med. 2008;358(14):1507-1508.
79. Akdim F, de Groot E, Kastelein JJP. Simvastatin with or without ezetimibe in familial hypercholesterolemia: the authors reply. N Engl J Med. 2008;359(5):532.
80. Akdim F, Kasstelein JJP, Gaudet D. The ENHANCE study and marketing ezetimibe. JAMA. 2008;299(23):2747.
81. Blake JA. Simvastatin with or without ezetimibe in familial hyper-cholesterolemia. N Engl J Med. 2008;359(5):531.
82. Brown BG. Simvastatin with or without ezetimibe in familial hyper-cholesterolemia: the editorialist replies. N Engl J Med. 2008;359(5): 532-533.
83. Connor WE. Simvastatin with or without ezetimibe in familial hyper-cholesterolemia. N Engl J Med. 2008;359(5):530.
84. David HR Jr, Murgolo NJ, Graziano MP. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 359(5):531.
85. Diamond GA, Kaul S. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;359(5):530.
86. Eichhorn EJ. Simvastatin with or without ezetimibe in familial hyper-cholesterolemia. N Engl J Med. 2008;359(5):529-530.
87. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009; 361:2113-2122.
88. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis): fnal results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010;55(24): 2721-2726.
89. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J. 2010;31:1633-1639.
90. Rizzo M, Rini GB, Spinas GA, Berneis K. The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes? Atherosclerosis. 2009;204(2):330-333.
91. Rossebo AB, Pedersen TR, Boman K, et al. SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343-1356.
92. Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S. At sea with SEAS: the frst clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy. Heart Lung Circ. 2009;18(5):343-346.
93. Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the improved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010;159(5):705-709.
94. http://www.clinicaltrials.org/(trials P025244, p05244, p05245, p04748, p02579). Accessed 2010 Jun 13.
95. Dreier JP, Endres M. Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology. 2004;62(4):670.
96. Fux R, Morike K, Gundel UF, Hartmann R, Gleiter CH. Ezetimibe and statin-associated myopathy. Ann Intern Med. 2004;140(8): 671-672.
97. Piedra Leon M, Garcia Unzueta MT, Otero Martinez M, Amado Senaris JA. Rabdomiolisis asociada a tratamiento combinado ezetimiba-statina. [Rhabdomyolysis associated to combined ezetimibe-statin treatment]. Rev Clin Esp. 2007;207(8):425-426.
98. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008;359:1357-1366.
99. Alsheikh-Ali AA, Karas RH. Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post-marketing analysis. J Clin Lipidol. 2008;3:138-142.
100. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolemia: screening strategy based on a meta-analysis. BMJ. 2007;335(7620):599.
101. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res. 2006;47(7):1339-1351.
102. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105(10):1413-1419.
103. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in the Netherlands. Atherosclerosis. 2010; 209:189-194.
104. Huijgen R, Versmissen J, Oosterveer DM, et al. Efficacy of 15 years of genetic cascade screening for familial hypercholesterolemia in the Netherlands in prevention of coronary artery disease. European Atherosclerosis Society. 2010 Jun 23; Hamburg, Germany. Abstract 1423.
105. Ross R. Atherosclerosis an infammatory disease. N Engl J Med. 1999;340(2):115-126.
106. Zilversmit DB. Relative atherogenicity of different plasma lipoproteins. Adv Exp Med Biol. 1978;109:45-59.
107. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AJP. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001; 357:577-581.